Are Persons Treated with Antidepressants and/or Antipsychotics Possibly Better Protected against Severe COVID 19?
- PMID: 33733436
- DOI: 10.1055/a-1408-8298
Are Persons Treated with Antidepressants and/or Antipsychotics Possibly Better Protected against Severe COVID 19?
Conflict of interest statement
Prof. Dr. Scherbaum has received honoraria for several activities (e. g., advisory board membership, lectures, manuscripts) from AbbVie, Camurus, Hexal, Janssen-Cilag, MSD, Medice, Mundipharma, Reckitt-Benckiser/Indivior, and Sanofi-Aventis. During the last three years he has participated in clinical trials financed by the pharmaceutical industry. Prof. Dr. Kuhn has received honoraria from Bayer, Janssen, Lundbeck, Neuraxpharm, Otsuka Pharma, Schwabe and Servier for lecturing at conferences and financial support to travel. He has received financial support for Investigator initiated trials from Medtronic GmbH. Priv. Doz. Dr. Kis has served on the advisory board of Medice and Takeda and has received honoraria for lectures, writing brochures from Medice, Takeda and Janssen-Cilag. He co-published diagnostic tools and manuals with the Hogrefe Publishing Group. Prof. Dr. Schaefer has received honoraria for lectures or travel support from Hexal, Servier, Gilead and Janssen-Cilag. Prof. Dr. Juckel, Dr. Cohen and Prof. Dr. Bonnet have nothing to declare here.
Comment on
-
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.JAMA. 2020 Dec 8;324(22):2292-2300. doi: 10.1001/jama.2020.22760. JAMA. 2020. PMID: 33180097 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources